Sertraline Linked to Lower Opioid Overdose Risk with Hydrocodone Compared to Other SSRIs: Study
Written By : Medha Baranwal
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2025-12-18 16:30 GMT | Update On 2025-12-18 16:31 GMT
Advertisement
USA: Sertraline appears to be the safest selective serotonin reuptake inhibitors (SSRIs) for patients using hydrocodone, showing a lower associated risk of opioid overdose compared with other SSRIs, a new study has revealed.
The new large-scale US cohort study published in BMC Medicine highlights important differences in overdose risk when hydrocodone is prescribed alongside commonly used
SSRIs are often prescribed together with opioid medications, especially in patients experiencing coexisting chronic pain and depressive symptoms. This overlap raises concerns, as hydrocodone relies on CYP2D6 and CYP3A4 metabolic pathways—enzymes that can be inhibited to varying degrees by different SSRIs. Such interactions could alter hydrocodone metabolism, potentially elevating the risk of overdose. Despite this concern, limited evidence existed regarding whether certain SSRIs may pose greater risks than others. To address this gap, researchers examined comparative overdose risks linked to specific SSRI–hydrocodone combinations.
The research team, led by Sungho Bea from Brigham and Women’s Hospital and Harvard Medical School, analysed insurance claims from both public and commercial US databases spanning 2004 to 2022. The study included 1.49 million adults who initiated one of five SSRIs—sertraline, citalopram, escitalopram, fluoxetine, or paroxetine—while already receiving hydrocodone. The key outcome was a hospitalisation or emergency department visit resulting from opioid overdose.
The study led to the following findings:
- The analysis using propensity score weighting and a weighted Cox proportional hazards model revealed significant differences in overdose risk among the SSRIs.
- Using sertraline as the reference, all four other SSRIs were associated with higher risks of opioid overdose.
- The hazard ratios were 1.21 for citalopram, 1.19 for escitalopram, 1.29 for fluoxetine, and 1.17 for paroxetine.
- Comparisons among citalopram, escitalopram, fluoxetine, and paroxetine showed no meaningful differences in risk.
- The findings indicate that sertraline stands out as the comparatively safer option among the SSRIs when used with hydrocodone.
The study’s conclusions remained consistent even with intention-to-treat analyses, though the associations were slightly weaker. No difference in overdose risk emerged when comparing citalopram, escitalopram, fluoxetine, and paroxetine with each other, reinforcing the unique lower-risk profile of sertraline in this context.
The authors acknowledged several limitations, including the possibility of unmeasured confounding due to absent data on illicit opioid use, CYP2D6 metaboliser status, or changes in clinical severity over time. The outcome definition captured only overdoses that resulted in hospital presentation, missing community-treated cases, especially those reversed with over-the-counter naloxone. Nevertheless, sensitivity analyses using alternative overdose definitions produced similar results, strengthening confidence in the findings.
"Overall, the study provides robust evidence that sertraline may be a safer SSRI choice for patients who require concurrent hydrocodone therapy. While all opioid–antidepressant combinations warrant close monitoring, these results may help clinicians make more informed prescribing decisions and tailor pharmacotherapy to minimise overdose risk," the authors concluded.
Reference:
Bea, S., Huybrechts, K.F., Glynn, R.J. et al. Opioid overdose associated with concomitant use of hydrocodone and selective serotonin reuptake inhibitors. BMC Med 23, 666 (2025). https://doi.org/10.1186/s12916-025-04475-3
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.